{"prompt": "['Novartis', 'Confidential', 'Page 8', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'Abbreviation', 'Explanation:', 'OAT3', 'organic anion transporter 3', 'OATP1B3', 'organic anion transporter P1B3', 'OC/RDC', 'Oracle Clinical/Remote Data Capture', 'PCR', 'protein-creatinine ratio', 'PEF', 'peak expiratory flow', 'PGD2', 'prostaglandin D2', 'P-gp', 'p-glycoprotein', 'PPS', 'per-protocol set', 'PRO', 'patient reported outcome', 'PT', 'prothrombin time', 'QM', 'quality management', 'QOL', 'quality of life', 'QTcF', 'Fridericia QT correction formula', 'RAST', 'radioallergosorbent test', 'SABA', 'short-acting \u00df-agonist', 'SAE(s)', 'serious adverse event(s)', 'SAF', 'safety analysis set', 'sCr', 'serum creatinine', 'SCR', 'screening', 'SD', 'standard deviation', 'SJS', 'Stevens-Johnson syndrome', 'SoC', 'standard of care', 'SOP', 'standard operating procedure', 'SUSAR', 'suspected unexpected serious adverse reactions', 'TBL', 'total bilirubin', 'TD', 'treatment discontinuation', 'TENS', 'toxic epidermal necrolysis', 'Th2', 'T helper 2', 'UGT', 'uridinediphosphate glucuronosyltransferase', 'ULN', 'upper limit of normal', 'WoC', 'withdrawal of consent', 'WHO', 'World Health Organisation', 'US', 'United States']['Novartis', 'Confidential', 'Page 9', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'Glossary of terms', 'Control drug', 'Drugs(s) used as a comparator to reduce assessment bias,', 'preserve blinding of investigational drug, assess internal study', 'validity, and/or evaluate comparative effects of the investigational', 'drug', 'Dosage', 'Dose of the study treatment given to the patient in a time unit (e.g.', '100 mg once a day, 75 mg twice a day)', 'Electronic data capture (EDC)', 'Electronic data capture (EDC) is the electronic acquisition of clinical', 'study data using data collection systems, such as Web-based', 'applications, interactive voice response systems and clinical', 'laboratory interfaces.', 'EDC includes the use of Electronic Case Report Forms (eCRFs)', 'which are used to capture data transcribed from paper source forms', 'used at the point of care.', 'eSource', 'eSource Direct Data Entry (DDE) refers to the capture of clinical', 'study data electronically, at the point of care. eSource', 'Platform/Applications reduce the use of paper capture source data', 'during clinical visits.', 'eSource combines source documents and case report forms', '(eCRFs) into one application, allowing for the real time collection of', 'clinical trial information to sponsors and other oversight authorities,', 'as appropriate.', 'Enrollment', 'Point/time of patient entry into the study at which informed consent', 'must be obtained (e.g. prior to starting any of the procedures', 'described in the protocol)', 'Epoch/Period', 'A portion of the study which serves a specific purpose. Typical', 'epoch/periods are: screening/recruitment, wash-out, treatment, and', 'follow-up', 'Investigational drug', 'The drug whose properties are being tested in the study; this', 'definition is consistent with US CFR 21 Section 312.3 and is', 'synonymous with \"investigational new drug\" or \"investigational', 'medicinal product.\"', 'Part', 'A single component of a study which contains different objectives or', 'populations within that single study. Common parts within a study', 'are: a single dose part and a multiple dose part, or a part in patients', 'with established disease and in those with newly-diagnosed', 'disease.', 'Patient ID', 'A unique number assigned to each patient upon signing the', 'informed consent', 'Randomization number', 'A unique identifier assigned to each randomized patient,', 'corresponding to a specific treatment arm assignment', 'Source data/Document', 'Source data refers to the initial record, document, or primary', 'location from where data comes. The data source can be a', 'database, a dataset, a spreadsheet or even hard-coded data, such', 'as paper or eSource.', 'Study drug/ treatment', 'Any single drug or combination of drugs administered to the patient', 'as part of the required study procedures; includes investigational', 'drug (s), placebo/comparator active drug run-ins or background', 'therapy']\n\n###\n\n", "completion": "END"}